Primrose Bio, a San Diego, CA-based company focused on developing and licensing its manufacturing technologies for nucleic acids and proteins used in therapeutics and vaccines, received an investment from 1315 Capital.
The amount of the deal was not disclosed.
The company intends to use the funds to enable the continued development and commercial expansion of its three offerings.
Led by CEO Dr. Helge Zieler, Primrose Bio was formed in 2023 through the merger of Primordial Genetics, Inc. and Pfenex to create an integrated end-to-end technology platform for solving complex drug manufacturing and design challenges. Its major offerings include Prima RNApols: improved enzymes for mRNA manufacturing, Pfenex Expression Technology: a validated production system, and PeliCRM197: a CRM197 conjugate vaccine carrier protein used in approved products.
Pharmaceutical companies use Primrose Bio’s technology, including Merck, Jazz Pharmaceuticals, Alvogen, Serum Institute of India, Arcellx, Arcturus and others.
FinSMEs
18/06/2024